San Francisco, CA, United States of America

Michael Garvin


 

Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2004-2008

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Michael Garvin: Innovator in Cholesterol Efflux Research

Introduction

Michael Garvin is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of cholesterol research, particularly through his innovative work on ATP binding cassette transporter protein ABC1. With a total of 3 patents, Garvin's inventions focus on enhancing cholesterol efflux and raising HDL levels.

Latest Patents

Garvin's latest patents include compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter protein ABC1. The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. It also encompasses recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as methods for producing ABC1 polypeptides. Furthermore, the invention includes antibodies that bind specifically to ABC1 polypeptides. In addition, it outlines methods for increasing cholesterol efflux and for enhancing ABC1 expression and activity. The invention further details methods for identifying compounds that modulate the expression of ABC1 and for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. Additionally, it provides kits and compositions suitable for screening compounds to determine their ABC1 expression modulating activity, as well as kits and compositions to assess whether a compound modulates ABC1-dependent cholesterol efflux.

Career Highlights

Michael Garvin is currently associated with Cv Therapeutics, Inc., where he continues to advance his research in cholesterol efflux mechanisms. His work has been instrumental in developing new therapeutic strategies for managing cholesterol levels in patients.

Collaborations

Garvin has collaborated with notable colleagues, including Richard M. Lawn and David Wade, who have contributed to his research endeavors.

Conclusion

Michael Garvin's innovative work in cholesterol efflux research has led to significant advancements in understanding and managing cholesterol levels. His contributions through multiple patents highlight his role as a key inventor in this important field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…